Tasly Diyi Pharmaceutical

Tasly Diyi Pharmaceutical is a prominent subsidiary of the Tasly Pharmaceutical Group, specializing in the research, development, and large-scale production of chemical drugs. Based in Huai'an, China, the company has established a robust portfolio focusing on oncology, central nervous system (CNS) disorders, and cardiovascular health. Its flagship product, Tijia (temozolomide), is a market leader in China for the treatment of brain tumors. The company operates advanced GMP-certified facilities and is transitioning from a traditional generic manufacturer to a developer of innovative chemical entities. Tasly Diyi plays a critical role in the parent group's chemical medicine segment, maintaining high standards in API synthesis and finished dosage forms.